These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30715819)

  • 1. panobinostat (FARYDAK°). Multiple myeloma: too toxic!
    Prescrire Int; 2016 Nov; 25(176):257-259. PubMed ID: 30715819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
    Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
    Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD
    Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
    Greig SL
    Target Oncol; 2016 Feb; 11(1):107-14. PubMed ID: 26826025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
    Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
    Moore DC; Arnall JR; Harvey RD
    J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
    Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
    Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
    Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
    Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
    Cavenagh JD; Popat R
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):501-507. PubMed ID: 29804873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panobinostat for the Treatment of Multiple Myeloma.
    Laubach JP; Moreau P; San-Miguel JF; Richardson PG
    Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
    Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV
    Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
    Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
    Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
    San-Miguel JF; Einsele H; Moreau P
    Adv Ther; 2016 Nov; 33(11):1896-1920. PubMed ID: 27677481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deacetylase inhibitors: an advance in myeloma therapy?
    Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
    Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.
    Maouche N; Kishore B; Bhatti Z; Basu S; Karim F; Sundararaman S; Collings F; Tseu B; Leary H; Ryman N; Reddy U; Vallance GD; Kothari J; Ramasamy K
    PLoS One; 2022; 17(7):e0270854. PubMed ID: 35797277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
    Pan D; Mouhieddine TH; Upadhyay R; Casasanta N; Lee A; Zubizarreta N; Moshier E; Richter J
    Semin Oncol; 2023; 50(1-2):40-48. PubMed ID: 37005144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.